Mostrar el registro sencillo del ítem

Her-2 positive mucinous carcinoma breast cancer, case report

dc.creatorGarcia Hernandez I.
dc.creatorCanavati Marcos M.
dc.creatorGarza Montemayor M.
dc.creatorLopez Sotomayor D.
dc.creatorPineda Ochoa D.
dc.creatorGomez Macias G.S.
dc.date2018
dc.date.accessioned2018-04-09T17:15:17Z
dc.date.available2018-04-09T17:15:17Z
dc.identifier.issn22102612
dc.identifier.doi10.1016/j.ijscr.2017.12.025
dc.identifier.urihttp://hdl.handle.net/11285/628072
dc.descriptionIntroduction Mucinous carcinoma is a variant of invasive breast carcinomas that accounts for 2% of them and has a better prognosis in contrast to the non-specific invasive carcinoma. They regularly are positive for estrogen and progesterone receptors and, generally, they do not overexpress HER2. When HER2 is positive, the first line treatment is trastuzumab; although the resistance is 52–89% for the non-specific carcinoma, it has been described just once in mucinous carcinoma. Case summary A 48-year-old female presented with a lump in her right breast and after a biopsy, it was diagnosed as mucinous carcinoma in the core biopsy and surgical resection, with positive hormone receptors and HER2 positive (3+) in 100% of the tumor cells. She was treated with neoadjuvant chemotherapy based on trastuzumab and pertuzumab with no pathological response. Discussion There are few pure mucinous carcinomas positive for HER2. Mucinous carcinomas are positive for HER2 account for less than 5% of invasive ductal carcinoma. Furthermore, our case was resistance to chemotherapy. Most mucinous carcinomas test negative for HER2, so they usually would not be treated with trastuzumab, in this case because the expression of HER2 in the biopsies we initiated it. Conclusion It's important to know that cases of mucinous carcinoma positive for HER2 exist and to be aware of the clinical problems that they may present: resistance to trastuzumab. Also, we need to understand the responsible mechanisms of this resistance and use immunohistochemistry for MUC which may predict it. © 2017
dc.languageeng
dc.publisherElsevier Ltd
dc.relationhttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85039702099&doi=10.1016%2fj.ijscr.2017.12.025&partnerID=40&md5=85dd92ef794ab544f3f3f18e3ba8927b
dc.rightsopenAccess
dc.sourceInternational Journal of Surgery Case Reports
dc.sourceScopus
dc.subjectepidermal growth factor receptor 2
dc.subjectestrogen receptor
dc.subjectmucin
dc.subjectpertuzumab
dc.subjectprogesterone receptor
dc.subjecttrastuzumab
dc.subjectadult
dc.subjectArticle
dc.subjectbreast biopsy
dc.subjectcancer adjuvant therapy
dc.subjectcancer cell
dc.subjectcancer combination chemotherapy
dc.subjectcancer diagnosis
dc.subjectcancer grading
dc.subjectcancer hormone therapy
dc.subjectcancer size
dc.subjectcancer surgery
dc.subjectcase report
dc.subjectcell size
dc.subjectclinical article
dc.subjectclinical feature
dc.subjectcolloid carcinoma
dc.subjectcytoplasm
dc.subjectdrug treatment failure
dc.subjecteosinophil
dc.subjectfamily history
dc.subjectfemale
dc.subjecthuman
dc.subjecthuman cell
dc.subjecthuman epidermal growth factor receptor 2 positive breast cancer
dc.subjectimmunohistochemistry
dc.subjectmiddle aged
dc.subjectneoadjuvant chemotherapy
dc.subjectpriority journal
dc.subjectsentinel lymph node biopsy
dc.subjectsimple mastectomy
dc.subjectsurgical margin
dc.subjecttreatment response
dc.subjecttumor biopsy
dc.titleHer-2 positive mucinous carcinoma breast cancer, case report
dc.typeArtículo
dc.identifier.volume42
dc.identifier.startpage242
dc.identifier.endpage246
refterms.dateFOA2018-04-09T17:15:17Z


Ficheros en el ítem

Thumbnail
Nombre:
1-s2.0-S2210261217306776.pdf
Tamaño:
2.157Mb
Formato:
PDF
Ver/

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem